Michal M, Gotti C
Centre for Toxicology and Biosciences, Carouge-Geneva, Switzerland.
Thromb Res. 1988 Sep 15;51(6):593-605. doi: 10.1016/0049-3848(88)90143-0.
Platelet-active drugs are of potential benefit in prevention of diabetic microangiopathy as well as other thromboembolic complications. The present investigation examines the effect of an angio-protective agent, calcium dobesilate (Doxium) on platelets and suggests its mechanism of action. Calcium dobesilate reduces aggregation and the release reaction induced by thrombin and collagen in rabbit platelets. Calcium dobesilate also increases platelet cAMP levels in vitro and ex-vivo. The experimental results indicate that the inhibitory effect of calcium dobesilate on platelet function is mediated through the cyclic AMP pathway, probably through activation of adenyl cyclase.
血小板活性药物在预防糖尿病微血管病变以及其他血栓栓塞性并发症方面具有潜在益处。本研究考察了一种血管保护剂——羟苯磺酸钙(多贝斯)对血小板的作用,并提出其作用机制。羟苯磺酸钙可降低兔血小板中由凝血酶和胶原蛋白诱导的聚集及释放反应。羟苯磺酸钙在体内外还可提高血小板环磷酸腺苷(cAMP)水平。实验结果表明,羟苯磺酸钙对血小板功能的抑制作用是通过环磷酸腺苷途径介导的,可能是通过激活腺苷酸环化酶实现的。